ABIONYX PHARMA SA (ABNX.PA) Stock Price & Overview
EPA:ABNX • FR0012616852
Current stock price
The current stock price of ABNX.PA is 3.16 EUR. Today ABNX.PA is down by -1.25%. In the past month the price decreased by -5.81%. In the past year, price increased by 143.08%.
ABNX.PA Key Statistics
- Market Cap
- 112.212M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.14
- Dividend Yield
- N/A
ABNX.PA Stock Performance
ABNX.PA Stock Chart
ABNX.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ABNX.PA. When comparing the yearly performance of all stocks, ABNX.PA is one of the better performing stocks in the market, outperforming 97.83% of all stocks.
ABNX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ABNX.PA. ABNX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ABNX.PA Earnings
ABNX.PA Forecast & Estimates
8 analysts have analysed ABNX.PA and the average price target is 10.71 EUR. This implies a price increase of 238.92% is expected in the next year compared to the current price of 3.16.
For the next year, analysts expect an EPS growth of -34.37% and a revenue growth -1.09% for ABNX.PA
ABNX.PA Groups
Sector & Classification
ABNX.PA Financial Highlights
Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS decreased by -28.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.18% | ||
| ROE | -83.55% | ||
| Debt/Equity | 0.59 |
ABNX.PA Ownership
ABNX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.31 | 36.326B | ||
| ARGX | ARGENX SE | 24.22 | 36.189B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.299B | ||
| ABVX | ABIVAX SA | N/A | 8.651B | ||
| 2X1 | ABIVAX SA | N/A | 8.556B | ||
| GXE | GALAPAGOS NV | N/A | 1.827B | ||
| GLPG | GALAPAGOS NV | N/A | 1.824B | ||
| NANO | NANOBIOTIX | N/A | 1.248B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.061B | ||
| PHIL | PHILOGEN SPA | 18.49 | 675.444M | ||
| GNFT | GENFIT | 855.88 | 436.525M | ||
| VLA | VALNEVA SE | N/A | 395.983M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ABNX.PA
Company Profile
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Company Info
IPO: 2015-03-30
ABIONYX PHARMA SA
Bat. D 33-43 Avenue Georges Pompidou
Balma OCCITANIE FR
Employees: 51
Phone: 33562249706
ABIONYX PHARMA SA / ABNX.PA FAQ
What does ABIONYX PHARMA SA do?
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
What is the current price of ABNX stock?
The current stock price of ABNX.PA is 3.16 EUR. The price decreased by -1.25% in the last trading session.
Does ABNX stock pay dividends?
ABNX.PA does not pay a dividend.
What is the ChartMill rating of ABIONYX PHARMA SA stock?
ABNX.PA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Who owns ABIONYX PHARMA SA?
You can find the ownership structure of ABIONYX PHARMA SA (ABNX.PA) on the Ownership tab.